News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premiumhere.

AcelRx Pharma (NASDAQ: ACRX) reported Q3 EPS of ($0.25), $0.02 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.89 million.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.